Krzysztof Selmaj

1955 -

country of citizenship: Poland

native language: Polish

languages spoken, written or signed: Polish

occupation: lecturer, researcher, physician, neurologist

award received: Prize of the Foundation for Polish Science, Gold Cross of Merit‎ (Poland)

Krzysztof Wojciech Selmaj (ur. 3 kwietnia 1955 w Łodzi) – polski lekarz, neurolog, profesor nauk medycznych. Source: Wikipedia (pl)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 118

Date

Title

Authors

2020-04-17

The Heat Shock Protein HSP70 Promotes Th17 Genes' Expression via Specific Regulation of microRNA

Marcin Mycko, Hanna Cwiklinska, Krzysztof Selmaj
2020-02-01

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Elżbieta Jasińska, Krzysztof Selmaj
2020-05-25

Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Xavier Montalban, Krzysztof Selmaj, Ralf Gold
2020-05-26

Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for the routinely used magnetic resonance imaging protocol in patients with multiple sclerosis

Krzysztof Selmaj, Agnieszka Słowik, Barbara Steinborn, Marcin Hartel, Monika Adamczyk-Sowa, Jarosław Sławek, Jerzy Walecki, Agata Majos, Konrad Rejdak, Sergiusz Jóźwiak, Halina Bartosik-Psujek, Marek Sąsiadek, Przemysław Nowacki, Ewa Krzystanek, Małgorzata Siger, Ewa Kluczewska, Robert Bonek, Zbigniew Serafin
2020-08-01

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Krzysztof Selmaj, Amit Bar-or, Anne H. Cross, Heinz Wiendl
2020-10-21

Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis

Krzysztof Selmaj, Agnieszka Słowik, Barbara Steinborn, Marcin Hartel, Monika Adamczyk-Sowa, Jarosław Sławek, Jerzy Walecki, Agata Majos, Konrad Rejdak, Halina Bartosik-Psujek, Alina Kułakowska, Sergiusz Jóźwiak, Marek Sąsiadek, Przemysław Nowacki, Ewa Krzystanek, Małgorzata Siger, Ewa Kluczewska, Robert Bonek, Zbigniew Serafin
2020-12-07

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

Thomas Berger, Krzysztof Selmaj, Monika Adamczyk-Sowa, László Vécsei, Konrad Rejdak, Zsolt Illes
2019-01-01

Novel emerging treatments for NMOSD

Krzysztof Selmaj
2019-02-20

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

Krzysztof Selmaj, Tjalf Ziemssen, Sven G Meuth
2019-11-23

Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials

Krzysztof Selmaj
2019-05-25

Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis

Marcin Mycko, Krzysztof Selmaj
2018-01-01

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Frauke Zipp, Xavier Montalban, Alan J. Thompson, Maria Pia Amato, Roland Liblau, Krzysztof Selmaj, Per Soelberg Sørensen, Maria Pia Sormani, Heinz Wiendl, Ralf Gold, David H. Miller, Hans-Peter Hartung, Ludwig Kappos
2018-01-19

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

Heinz Wiendl, Frauke Zipp, Xavier Montalban, Alan J. Thompson, Susana Otero-Romero, Maria Pia Amato, Roland Liblau, Krzysztof Selmaj, Per Soelberg Sørensen, Maria Pia Sormani
2018-01-01

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Hans-Peter Hartung, Ludwig Kappos, Giancarlo Comi, Gavin Giovannoni, Krzysztof Selmaj, Amit Bar-or, Stephen L. Hauser, Eva Havrdová, Douglas L Arnold, Fred D. Lublin, Shibeshih Belachew, Anthony Traboulsee, Hideki Garren
2018-10-05

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

Krzysztof Selmaj
2018-07-25

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Krzysztof Selmaj, Xavier Montalban, Amit Bar-or
2018-11-23

Follow-on glatiramer acetate

Christian Wolf, Krzysztof Selmaj
2017-08-01

New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland

Krzysztof Selmaj
2017-05-08

Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition

Anna Jurewicz, Malgorzata Domowicz, Grazyna Galazka, Krzysztof Selmaj, Cedric S Raine
2017-10-01

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE

Heinz Wiendl, Krzysztof Selmaj
2017-08-02

Multiple sclerosis: Skin-induced antigen-specific immune tolerance.

Krzysztof Selmaj
2017-01-01

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.

Christian Wolf, Krzysztof Selmaj, Frederik Barkhof, Evelyn van den Tweel
2016-07-26

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Krzysztof Selmaj, Xavier Montalban, Ralf Gold
2016-06-01

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations

Krzysztof Selmaj, Ralf Gold
2016-07-13

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

Krzysztof Selmaj, Eva Havrdová, Ralf Gold
2016-07-05

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study

Tjalf Ziemssen, Hans-Peter Hartung, Olaf Stüve, Ludwig Kappos, Krzysztof Selmaj, Xavier Montalban, Mark S Freedman, Bernhard Hemmer, Peter Rieckmann, Erik Wallström
2016-02-01

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis

Till Sprenger, Krzysztof Selmaj
2016-12-21

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Hans-Peter Hartung, Ludwig Kappos, Giancarlo Comi, Gavin Giovannoni, Krzysztof Selmaj, Amit Bar-or, Stephen L. Hauser, Xavier Montalban, Douglas L Arnold, Kottil W Rammohan, Fred D. Lublin, Shibeshih Belachew, Bernhard Hemmer, Anthony Traboulsee, Donna Masterman, Hideki Garren, Nicole Mairon, Jerry S Wolinsky
2016-12-21

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Krzysztof Selmaj, Hans-Peter Hartung, Ludwig Kappos, Giancarlo Comi, Gavin Giovannoni, Regina Maria Papais-Alvarenga, Frauke Zipp, Amit Bar-or, Stephen L. Hauser, Xavier Montalban, Douglas L Arnold, Kottil W Rammohan, Fred D. Lublin, Shibeshih Belachew, Bernhard Hemmer, Anthony Traboulsee, Donna Masterman, Hideki Garren, Nicole Mairon, Jerry S Wolinsky
2016-10-12

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Krzysztof Selmaj, Eva Havrdová, Hans-Peter Hartung, Gavin Giovannoni
2016-05-11

Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies

Ludwig Kappos, Gavin Giovannoni, Krzysztof Selmaj, Ralf Gold, Bhupendra O Khatri, Marianne T Sweetser, Steven Greenberg, Jacob Elkins
2016-08-08

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.

Robert Zivadinov, Krzysztof Selmaj

Human - wd:Q28672635

Welcome to Inventaire

the library of your friends and communities

learn more